Table 4 Intratumoral injection of C. novyi-NT for cancer therapy
From: Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy
Classification | Therapeutic strategy | Phase | Tumor type | Effect | Ref |
|---|---|---|---|---|---|
Pre-clinical | Intratumoral injection | NA | Spontaneous solid tumors | Well tolerated, objective response was 37.5% | |
Branched gold nanoparticle-coated spores | Prostate cancer | Significant antitumor response | |||
Clinical treatment/trial | Intratumoral injection | I | Injectable, treatment-refractory solid tumors | Significant but manageable toxicity, tumor-confined cell lysis, and enhance systemic tumor-specific T-cell responses | NCT01924689214 |
I | Treatment-refractory solid tumor malignancies | No results posted | NCT00358397 | ||
I | Treatment-refractory solid tumor malignancies | No results posted | NCT01118819 | ||
I | Advanced leiomyosarcoma | Reduction of tumor burden, killed and necrotized tumor cells | NCT01924689212 | ||
I | Treatment-refractory solid tumors | No results posted | NCT03435952 |
